Nutritional Supplementation on Physiological and Metabolic Markers in Females
A Pilot Study Investigating the Effects of a Nutritional Supplement on Physiological and Metabolic Markers in 38-55-year-old Females
The goal of this clinical trial is to learn if a 12-week nutritional supplement can result in significant changes in the body composition of 38-55-year-old females. The main questions it aims to answer are:
- Does a 12-week nutritional supplementation with myo-inositol, berberine, cinnamon, and chromium lead to significant changes in body composition (e.g. body mass index, body fat composition) in females aged 38-55 compared to placebo?
- Does a 12-week nutritional supplementation with myo-inositol, berberine, cinnamon, and chromium lead to significant changes in small molecules (metabolites) in plasma and urine, menopause-related symptoms, and physical performance (e.g. grip strength) in females aged 38-55 compared to placebo? Researchers will compare the nutritional supplement to a placebo (a look-alike substance that contains no nutritional supplement) to see if the intervention works to change body composition in females aged 38-55.
Participants will:
- Sign a consent form before any procedures begin
- Attend two visits to the clinical research facility at Southampton General Hospital over 12 weeks.
- Fast before visit's and provide blood and urine samples at each visit
- Undergo measurements at each visit, including waist and hip circumferences, grip and leg strength, and body composition.
- Complete questionnaires about general health, menopause-related changes, alcohol consumption, physical activity, and diet.
- Take 1 capsule 3 times a day at the onset of a meal (once in the morning, once at midday, and once in the evening) for the first 10 days.
- Take 3 capsules 3 times a day at the onset of a meal (once in the morning, once at midday, and once in the evening) from day 11 to day 84.
- Record supplement intake in a daily compliance diary during the study
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Menopause is defined as the reproductive condition of amenorrhea for 12 months, as a result of reduced activity of ovarian follicles and hormonal changes, including oestrogen, androgens, and progesterone. Globally, approximately 47 million females transition into menopause annually. Hormonal decline can reflect in several physical, mental, and genitourinary symptoms. Common physical manifestations include sleep disturbance, hot flushes, mood changes, night sweats, and fatigue.
The current average age at menopause in the United Kingdom is 51 years, typically occurring between 45 and 55; however, a significant number of females experience menopause earlier than expected. When menopause occurs before the normal age, it may be classified as premature (before 40 years), early (between 40-45 years), or induced menopause (result of bilateral oophorectomy with or without hysterectomy, removal of the ovaries and fallopian tubes, or ovarian ablation through radiation therapy).
Menopause-related physical and metabolic changes are mainly a consequence of oestrogen deficiency, affecting lipid metabolism, insulin resistance, energy consumption, and body fat composition. Changes in body composition during menopause often lead to an increase in body mass index (BMI), particularly due to higher fat accumulation and reduced lean muscle mass. During perimenopause, females experience progressive weight gain at an estimated rate of 1.5 kg per year, resulting in an average increase of approximately 10 kg by the time menopause is reached. Higher BMI during menopause has been linked with an elevated risk of cardiovascular and metabolic diseases.
To address these menopause-associated changes, several therapeutic approaches are utilised, including both hormonal and non-hormonal strategies. Natural nutritional supplements have emerged as promising options because of their potential benefits. Among these, cinnamon extracts have gained attention due to their anti-inflammatory, cardiovascular, and immunomodulatory properties, which may alleviate postmenopausal symptoms. Alongside cinnamon, myo-inositol has been shown to alleviate vasomotor symptoms, improving lipid and glucose metabolism and reducing cardiovascular risk factors. By targeting changes in body composition during menopause, nutritional supplements represent a strategic approach to improving quality of life for menopausal females.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Colleen S Deane, PhD
- Número de telefone: +44 2381208664
- E-mail: c.s.deane@soton.ac.uk
Estude backup de contato
- Nome: Veronica F Santiago, PhD
- Número de telefone: +44 2381208664
- E-mail: V.F.Santiago@soton.ac.uk
Locais de estudo
-
-
Hampshire
-
Southampton, Hampshire, Reino Unido, SO16 6YD
- Recrutamento
- NIHR Southampton Clinical Research Facility
-
Contato:
- Clinical Research Facility
- Número de telefone: 02381204989
- E-mail: crfstudyteam@uhs.nhs.uk
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Assigned sex at birth is female
- Aged 38-55 years
Experiencing irregular menstrual cycles but not amenorrheic for more than 12 months or have at least one of the following recent symptoms (i.e., from 38 years onwards): (1) hot flushes, (2) sleep disturbances, (3) mood swings, (4) concentration difficulties, (5) bloating or (6) weight gain.
- Willing to avoid taking other food supplements during the study period
- Able to provide written informed consent
Exclusion Criteria:
- Diabetes
- BMI <18.5 kg/m2
- Pregnant or trying to get pregnant
- No active cancer or cancer within last 5 years
- Total Hysterectomy
- Known allergies to cinnamon extract, chromium, berberine, myo-inositol
- Currently taking part in research, or have done within the last 3 months
- Diagnosed autoimmune diseases
- Diagnosed hypoglycemia
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Nutritional supplement
Nutritional supplement:
|
Nutritional Supplement (myo-inositol, berberine, cinnamon, chromium) composed of 4 natural bioactives extracted from plants, including fruits, roots, barks, and grains.
|
|
Comparador de Placebo: Placebo
Placebo:
|
Placebo: Maltodextrin
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Body mass index
Prazo: At the baseline visit and at the end of 12 weeks intervention
|
To compare the body mass index by measuring the weight after 12-week intervention
|
At the baseline visit and at the end of 12 weeks intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Body fat composition
Prazo: At the baseline visit and at the end of the 12-week intervention
|
To compare the effect of a 12-week nutritional intervention versus placebo by measuring Waist and hip circumferences
|
At the baseline visit and at the end of the 12-week intervention
|
|
Metabolomic profile of the plasma sample
Prazo: At the baseline visit and at the end of 12 weeks intervention
|
To compare the effect of a 12-week nutritional intervention to a placebo on the plasma metabolome
|
At the baseline visit and at the end of 12 weeks intervention
|
|
Metabolomic profile of a urine sample
Prazo: At the baseline visit and at the end of 12 weeks intervention
|
To compare the effect of a 12-week nutritional intervention versus placebo on the urinary metabolome.
|
At the baseline visit and at the end of 12 weeks intervention
|
|
Menopause-related changes
Prazo: At the baseline visit and at the end of 12 weeks intervention
|
To compare the effect of a 12-week nutritional intervention on self-reported menopause-related changes versus placebo.
|
At the baseline visit and at the end of 12 weeks intervention
|
|
Hand grip dynamometry
Prazo: At the baseline visit and at the end of 12 weeks intervention
|
To compare the effect of a 12-week nutritional intervention versus placebo on grip strength
|
At the baseline visit and at the end of 12 weeks intervention
|
|
Portable strength tracking system
Prazo: At the baseline visit and at the end of the 12-week intervention
|
To compare the effect of a 12-week nutritional intervention versus placebo on leg strength
|
At the baseline visit and at the end of the 12-week intervention
|
|
Transcriptomic profile of blood sample
Prazo: At the baseline visit and at the end of the 12-week intervention
|
To compare the effect of a 12-week nutritional intervention versus placebo on the blood transcriptome
|
At the baseline visit and at the end of the 12-week intervention
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Colleen S Deane, PhD, University of Southampton
Publicações e links úteis
Publicações Gerais
- Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014 Oct;43(5):1542-62. doi: 10.1093/ije/dyu094. Epub 2014 Apr 26.
- El Khoudary SR, Greendale G, Crawford SL, Avis NE, Brooks MM, Thurston RC, Karvonen-Gutierrez C, Waetjen LE, Matthews K. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019 Oct;26(10):1213-1227. doi: 10.1097/GME.0000000000001424.
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012 Apr;97(4):1159-68. doi: 10.1210/jc.2011-3362. Epub 2012 Feb 16.
- Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011. doi: 10.1210/jc.2015-2236. Epub 2015 Oct 7.
- Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1-15. doi: 10.1210/clinem/dgaa764.
- Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med. 2005 Dec 19;118 Suppl 12B:14-24. doi: 10.1016/j.amjmed.2005.09.031.
- Mainini G, Ercolano S, De Simone R, Iavarone I, Lizza R, Passaro M. Dietary Supplementation of Myo-Inositol, Cocoa Polyphenols, and Soy Isoflavones Improves Vasomotor Symptoms and Metabolic Profile in Menopausal Women with Metabolic Syndrome: A Retrospective Clinical Study. Medicina (Kaunas). 2024 Apr 4;60(4):598. doi: 10.3390/medicina60040598.
- Refaei M, Karami Z, Kazemi F, Moradkhani S, Masoumi SZ, Jenabi E, Jafari M. Cinnamon potential in alleviating early postmenopause symptoms: a randomized clinical trial. Menopause. 2024 Dec 1;31(12):1078-1084. doi: 10.1097/GME.0000000000002444.
- Jeong HG, Park H. Metabolic Disorders in Menopause. Metabolites. 2022 Oct 8;12(10):954. doi: 10.3390/metabo12100954.
- Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women's cardiovascular health: is it really an obvious relationship? Arch Med Sci. 2022 Dec 10;19(2):458-466. doi: 10.5114/aoms/157308. eCollection 2023.
- Lambrinoudaki I, Paschou SA, Armeni E, Goulis DG. The interplay between diabetes mellitus and menopause: clinical implications. Nat Rev Endocrinol. 2022 Oct;18(10):608-622. doi: 10.1038/s41574-022-00708-0. Epub 2022 Jul 7.
- Fenton A. Weight, Shape, and Body Composition Changes at Menopause. J Midlife Health. 2021 Jul-Sep;12(3):187-192. doi: 10.4103/jmh.jmh_123_21. Epub 2021 Oct 16.
- Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F, Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol. 2011 Dec;118(6):1271-1279. doi: 10.1097/AOG.0b013e318236fd12.
- Adamopoulos DA, Karamertzanis M, Thomopoulos A, Pappa A, Koukkou E, Nicopoulou SC. Age at menopause and prevalence of its different types in contemporary Greek women. Menopause. 2002 Nov-Dec;9(6):443-8. doi: 10.1097/00042192-200211000-00010.
- Shadyab AH, Macera CA, Shaffer RA, Jain S, Gallo LC, Gass ML, Waring ME, Stefanick ML, LaCroix AZ. Ages at menarche and menopause and reproductive lifespan as predictors of exceptional longevity in women: the Women's Health Initiative. Menopause. 2017 Jan;24(1):35-44. doi: 10.1097/GME.0000000000000710.
- Anto A, Basu A, Selim R, Eisingerich AB. Women's Menopausal Experiences in the UK: A Systemic Literature Review of Qualitative Studies. Health Expect. 2025 Feb;28(1):e70167. doi: 10.1111/hex.70167.
- Koo S, Ahn Y, Lim JY, Cho J, Park HY. Obesity associates with vasomotor symptoms in postmenopause but with physical symptoms in perimenopause: a cross-sectional study. BMC Womens Health. 2017 Dec 8;17(1):126. doi: 10.1186/s12905-017-0487-7.
- Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024 Oct;27(5):466-472. doi: 10.1080/13697137.2024.2380363. Epub 2024 Jul 30.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ERGO111652
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .